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 
Abstract— A novel electro-generated chemiluminescence 
method for the determination of methotrexate (2,4-diamino-
N10-methyl pteroyl glutamic acid) in pharmaceutical 
formulations is proposed. The method was based on the 
chemiluminescence (CL) emission intensity produced as a result 
of the electrochemical oxidation of the  into the 
active  form, which then reacts with the 
methotrexate and produces light. 
Reaction variables were thoroughly investigated. The 
optimum conditions were incorporated in the procedure. 
Linear calibration curve were obtained for signal in mV versus 
concentration in mol L  in the range 0-21×10  M with 
percentage relative standard deviation of less than 2% (n = 6) 
and correlation coefficient of r = 0.99986. The method 
described here proved to be very convenient and easy to use for 
the assay of methotrexate in drug formulations. This method 
was tested by the determination of methotrexate in different 
drugs containing known concentration. 
 
 
Index Terms— Flow injection electro-generated 
chemiluminescence, methotrexate (MTX), Tris(2,2'-bipyridyl) 
ruthenium(II) reagent. 
 
I. INTRODUCTION 
  Methotrexate (2,4-diamino-N
10
-methyl-pteroglutamic 
acid, is widely used for the treatment of cancer. Vast number 
of reports have shown that it is highly effective in the 
treatment of Leukemia and other types of cancer such as 
Osteosarcoma, Choriocarcinoma and non-Hodgkin's 
Lymphoma. Its action is the shutting down of multiplication 
of cells [1,2]. 
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Several methods of determination of methotrexate have been 
reported. These methods including enzymatic assay [3], 
fluorescence [4], spectrometry [5-9], chromatography 
[10,11] and electrophoresis [12]. The development of high 
performance liquid chromatography and electrophoresis 
have the potential to detect both the intact molecule and its  
metabolities. However, these techniques require 
considerable instruments and expensive columns and long 
time for sample preparation and analysis. In this paper, we 
report an electro-generated chemiluminescence (ECL) for 
the determinations of methotrexate in pharmaceutical 
preparations. Sensitivity and linearity of the method will be 
discussed and our result is going to be compared with 
chemiluminescent method. 
 
Figure 1.Schematic diagram of FIA-ECL system for ECL 
determination of methotrexate. 
E = Electrical cell, r1& r2 = Reagent, S = Sample, C = coil, D 
= PMT, R = Recorder. 
 
To the best of our knowledge, no chemiluminescence 
method has been yet used for the determination of 
methotrexate in pharmaceutical preparations. The proposed 
method describes a highly sensitive way for the 
determination of methotrexate using flow injection analysis-
electro-generated chemiluminescence (CFIA-ECL) system 
(Fig. 1). The ECL method is based on the reaction of 2,2'-
bipyridyl-ruthenium(II) and methotrexate as the chemical 
reductant. 
II. EXPERIMENTAL 
2.1 Materials and Reagents 
All chemicals used in this work were of analytical grade 
(AnalaR) and all solutions were prepared using distilled 
water throughout. A solution of 1×10  M Tris(2,2'-
bipyridyl) dichloro ruthenium(II) hexahydrated, 
 (Aldrich, USA) was prepared in 0.05 M 
Electro-generated Chemiluminescent Determination 
of Methotrexate in Pharmaceutical Preparations by 
Tris (2,2'-bipyridine)ruthenium(II) Using Flow 
Injection 
Mohammad A. Abdalla, Ibrahim Z. Al-Zamil, Saad A. Al-Tamrah, Telal S. Omar 
 Electro-generated Chemiluminescent Determination of Methotrexate in Pharmaceutical Preparations by Tris 
(2,2'-bipyridine)ruthenium(II) Using Flow Injection 
 
                                                                                                 80                                                                            www.ijeas.org 
sulfuric acid (DBH Ltd, UK). Methotrexate standard 
material was supplied from (Sigma, UK). 
2.2 Instrumentation 
The CL and ECL measurements were made with home 
built flow-injection cell. Potentials were applied to the two 
platinum electrodes. 
In the case of ECL, one electrode is oxidizing 
 and at the same time reduction of 
 occurs at the surface of the other electrode. 
Enough period of time was allowed for the oxidation of 
to . Samples were then mixed 
with  solution producing CL just before the 
photomultiplier detector. Measurements of the emitted 
radiation intensity were made by a sensitive photomultiplier 
tube (PMT) (Thorn EMI, 9789 QB). 
The PMT used were operated at 1100 V, provided by a 
stable high voltage power supply (Thorn EMI, model PM 
28BN), and so wavelength selection was involved. A 4-
channel peristaltic pump (Gilson Miniplus 3MP4) was used 
to deliver the reagent and the samples. 
A solenoid activated rotary valve (Rheodyne 5020) was 
used to inject the sample solution into reagent stream of 
1×10  M  in 0.05 M H2SO4. 
Polytrifluoroethylene (PTFE) of 0.06 mm internal diameter 
was used throughout the manifold and a strip-chart recorder 
RECIII, (Amersham Pharmacia Biotech) was fed to the 
PMT and the height of the peak was measured manually. 
2.3 Standard solution 
A stock solution containing 0.01 g of methotrexate in 
) was prepared. 
2.4.1 General procedure 
The reagent solution used for the electro-generated 
chemiluminescence [1.0×10
-3
 M.  in 0.05 M 
sulfuric acid] was fed by the peristaltic pump at a flow rate 
. Oxidation of  to  
was care using platinum electrodes that is held at a voltage 
of 0.8 V for a peroxide of 80 min. 
Working standard solutions of methotrexate were 
prepared from the stock solution in the range 
0.1×10  M. A 25 ml portion of each 
methotrexate solution was injected into a cancer stream of 
reagent solution and the resulting peak heights were 
recorded. Calibration graphs were prepared by plotting 
ECL/CL intensities (mV) versus the sample molar 
concentrations. Accordingly, the corresponding regression 
equations were calculated. 
a) 2.5 Optimization of experimental variables 
For the analysis of methotrexate in pharmaceutical 
preparations ten powdered tablets equivalent to 10 mg of 
methotrexate were transferred into 100 ml volumetric flask 
and completed to volume with distilled water. The flask with 
its contents was sonicated for 5 minutes and then filtered. 
In order to the medium used for the electro-generated 
chemiluminescence reaction to fulfill certain criteria, 
reaction variables were thoroughly investigated. In each 
time, changing one variable in every turn and keeping the 
others at their optimum conditions 
2.5.1 Effect of the oxidation potential of  
reagent 
The applied potential used for the oxidation of 
 reagent was investigated in the range between 
(0.2-1.4 V). The highest ECL emission was obtained at 0.80 
V which was used for the determination. 
2.5.2 Effect of sulfuric acid concentration as a carrier 
stream of  
Oxidation potential of  is increased by the 
use of sulfuric acid as a solvent. The effect of sulfuric acid 
concentration (0.01-2 M) on the ECL signal was 
investigated. It was found that ECL signal increases with 
increasing sulfuric acid concentration and the highest signals 
were obtained with 0.5 M sulfuric acid. Thus, 0.5 M acid 
concentration was used in the preparation of the reagent 
throughout methotrexate determination. 
2.5.3 Effect of  concentration 
The effect of the reagent concentration on the signal of 
methotrexate was studied using concentrations in the range 
1×10 -5×10  M  prepared in 0.5 M sulfuric 
acid. It can be seen clearly from (Fig. 2) that the ECL signals 
were increased with increasing of  
concentration and the highest intensity of the signal was 
observed at the concentration 4×10  M  after 
this concentration the signal height start decreasing. This 
may result due to quenching of ECL signal by means of self-
absorption of emitted radiation. 
2.5.4 Effect of reagent flow rate 
After optimizing the concentrations of the reagents, 
attention were then concentrated on the effect of the reagents 
flow rate. The flow rate is an essential parameter and its 
variation has the greatest influence on the light of the signal 
obtained. The effect of flow rate was studied after keeping 
all other parameters constant, i.e. the solution of 
 of 0.004 M in 0.5 M sulfuric acid was then 
introduced into the manifold at different solution flow rate. 
Increasing the flow rate tend to increase the signal height up 
to 2.2 ml min  after which it start to decrease. This flow 
rate is fairly high enough and therefore was chosen to enable 
the excited reaction product to reach the detector in a 
minimum time. Therefore, 2.2 ml min  was chosen as the 
best flow rate. At this flow rate, the consumption of the 
reagent is the minimum. 
2.5.5 Effect of the sample volume 
The effect of the sample volume in the range of 10-100 
loop connected to the injection valve. It was found that the 
signal height of ECL of methotrexate increase sharply with 
the increase of the sample volume between 10-
Concentration after that 50-100 ml of methotrexate tend to 
was chosen as the optimum sample volume for a complete 
reaction without more consumption of the analyte. 
2.5.6 Effect of the reaction coil length 
The effect of the length of the reaction coil on the ECL 
signal height was studied in the range 10-150 cm. (Fig. 2) 
show the effect of the reaction coil length on the ECL 
intensity. When the coil length is taller than 40 cm, the 
height of the signal start decreasing notably most probably 
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because the reaction completes away from the PMT. 
Therefore, 40 cm length were chosen throughout this study. 
 
Figure 2.Effect of concentration of on methotrexate 
determi
-1
). 
III.  VALIDATION 
3.1.1 Linearity range 
The calibration graph for the determination of 
methotrexate by the proposed method was made by plotting 
the ECL intensity versus the concentration of methotrexate. 
The linearity of calibration graph was found to be over the 
concentration range 0-21×10  M. The calibration graph 
was found to be recliner over the concentration range as seen 
in Tab. 1 and Fig. 3. 
Table 1.Percentage analytical recovery. 
Pharmaceutical 
preparation 
Concentration 
×10 mol l * 
Recovery 
(%) 
Taken Found 
Methotrexate Tablets 
(Each tablet contains 
MTX  
equivalent to MTX 
2.5 mg) 
3.0 3.006 100.21 
7.0 7.010 100.14 
11.0 10.926 99.33 
15.0 14.970 99.80 
19.0 19.083 100.44 
Mean ± S.D. 99.98±0.44 
* mean of three readings. 
3.1.2Accuracy and precision 
To check the accuracy of the proposed method 
percentage error was determined over the concentration 
range 0-21×10  M. The % error was recorded in Tab. 1. 
Table 2 shows the statistical evaluation of the proposed 
method. 
Table 2.Statistical analysis for FIA-ECL determination of 
methotrexate. 
Parameter Short range 
Linear range 0.18-168 ppm 
Regression equation y = 10.67 x + 13.262 
Correlation coefficient 0.9998 
Standard deviation of 
intercept 
0.033 
Standard deviation of slope 0.0014 
LOD 0.018 ppm 
LOQ 0.18 ppm 
 
Figure 3.Calibration curve. 
 
3.1.3Ruggedness 
In order to evaluate the ruggedness of the method, the 
intraday and interday precisions were evaluated as is seen 
from Tab. 3. The precision of the proposed ECL method was 
fairly high, as indicated in the table by low values of relative 
standard deviation. 
 
Table 3.Precision data for the determination of methotrexate 
by the proposed FIA-ECL method. 
 
Parameter 
Methotrexate concentration 
Short range (ppm) Long range (ppm) 
Found 
2.5 5 10 10 20 30 
100.34 100.5 99.4 100.4 100.2 99.9 
99.8 99.3 100.3 100.2 100.4 99.4 
Mean 100.2 99.6 99.6 100.1 100.3 99.7 
%RSD 0.73 0.60 0.81 0.80 0.91 0.88 
Each result is the average of six separate experiments. 
 
3.4Applications 
3.4.1 Analysis of methotrexate 
The proposed method has showed a high sensitivity 
which allowed the determination of methotrexate in 
pharmaceutical preparations. The nominal content of 
methotrexate in the pharmaceutical preparation or 
methotrexate tablets was determined using the corresponding 
regression equation. Tab. 4 shows the obtained result. A 
statistical comparison of the proposed method with the CL 
method is shown in Tab. 5. The t-test value obtained indicate 
that there is no significant difference between the two 
methods, however, the calibration graphs of the ECL has the 
advantages over the CL of being superior when sample 
solution of lower concentration are to be analyzed. 
Table 4.Determination of Methotrexate in some 
pharmaceutical preparation. 
Pharmaceutical 
preparation 
Concentration 
×10  M 
Recovery 
% 
Methotrexate tablets 
Each tablet contains 
methotrexate  
equivalent to MT × 2.5 mg 
3.0 3.006 100.21 
7.0 7.01 100.14 
11.0 10.926 99.33 
15.0 14.970 99.80 
19.0 19.083 100.44 
Mean ± SD 99.98±0.44 
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Table 5. Comparison of results obtained for the 
determination of methotrexate using the proposed FIA-ECL 
and FIA-CL methods 
Pharmaceutical preparation % Found ± RSD 
Methotrexate tablets 
Each tablet contains 
methotrexate equivalent to 
MT × 2.5 mg 
FIA-CL FIA-ECL 
99.82±0.51 99.98±0.44 
f-values (6.59) 1.12 1.5 
t-values (2.365) 1.56 1.09 
 
3.4Electro-generated chemiluminescenct mechanism 
The proposed mechanism is as follows:  is 
oxidized electrochemically at the surface of the platinum 
electrodes at the appropriate voltage. The methotrexate is 
reduced to form an intermediate ion radical which is reacts 
with the  to form . This is then 
reduces  to the excited state that emits light. 
The proposed mechanism of methotrexate may be shown as 
follows: 
 at the surface of the 
electrode. 
 + methotrexate methotrexate+. + 
 
+ methotrexate
+.
 + H2O  methotrexate 
+ H
+
 +  
  +    + 
 
    
 
IV. CONCLUSION 
Our proposed Flow Injection-Electro-generated 
Chemiluminescence (FI-ECL) has proven to be suitable and 
sensitive for the determination of methotrexate in 
pharmaceutical preparations. The oxidation of  
is selective, that means lower concentration of methotrexate 
will not be oxidized as in the case of chemiluminescence 
utilizing potassium permanganate which otherwise oxidize 
the drug itself. 
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